Your browser doesn't support javascript.
loading
ABSTRACT
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Thrombosis / Stents / Coronary Disease / Drug-Eluting Stents / Drug Liberation / Korea Type of study: Clinical_trials / Guideline Limits: Humans Country/Region as subject: Asia Language: En Journal: Korean Circulation Journal Year: 2017 Type: Article
Full text: 1 Index: WPRIM Main subject: Thrombosis / Stents / Coronary Disease / Drug-Eluting Stents / Drug Liberation / Korea Type of study: Clinical_trials / Guideline Limits: Humans Country/Region as subject: Asia Language: En Journal: Korean Circulation Journal Year: 2017 Type: Article